Selected outcomes in 2012

During working and utilization of our large research infrastructure BBMRI.cz were created plenty of unique outcomes. Here we mention some of them:

Demlova, R., Obermannova, R., Valik, D., Vyzula, R. Phase I Trial in Oncology – theory and practice. Klin Onkol 2012;25(Suppl2):2S98–2S101. doi: 10.14735/amko20122S98. (bez IF)
Faktor, J., Dvorakova, M., Maryas, J., Struharova, I., Bouchal, P. Identification and characterisation of pro-metastatic targets, pathways and molecular complexes using a toolbox of proteomic technologies. Klin Onkol 2012;25(Suppl2):2S70–2S77. doi: 10.14735/amko20122S70. (bez IF)
Faltejskova, P., Besse, A., Sevcikova, S., Kubiczkova, L., Svoboda, M., Smarda, J., Kiss, I., Vyzula, R., Slaby, O. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis 2012;27(11):1401-1408. doi: 10.1007/s00384-012-1461-3. (IF2011: 2,385)
Faltejskova, P., Svoboda, M., Srutova, K., Mlcochova, J., Besse, A., Nekvindova, J., Radova, L., Fabian, P., Slaba, K., Kiss, I., Vyzula, R., Slaby, O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012;16(11):2655-2666. doi: 10.1111/j.1582-4934.2012.01579.x. (IF2011: 4,125)
Hezova,, Kovarikova, A., Bienertova-Vasku, J., Sachlova, M., Redova, M., Vasku, A., Svoboda, M., Radova, L., Kiss, I., Vyzula, R., Slaby, O. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol 2012;18(22):2827-2831. doi: 10.3748/wjg.v18.i22.2827. (IF2011: 2,471)
Holub,, Greplova, K., Knoflickova, D., Nenutil, R., Valik, D. The Biobanking Research Infrastructure BBMRI_CZ: A Critical Tool to Enhance Translational Cancer Research. Klin Onkol 2012;25(Suppl2):2S78–2S81. doi: 10.14735/amko20122S78. (bez IF)
Kalousová,, Krechler, T., Jáchymová, M., Kuběna, A.A., Zák, A., Zima, T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol 2012;33(5):1695-1700. doi: 10.1007/s13277-012-0426-z. (IF2011: 2,143)
Orzol,, Nekulova, M., Vojtesek, B., Holcakova, J. p63 - an important player in epidermal and tumour development. Klin Onkol 2012;25(Suppl2):2S11–2S15. doi: 10.14735/amko20122S11. (bez IF)
Redova, M., Poprach, A., Nekvindova, J., Iliev, R., Radova, L., Lakomy, R., Svoboda, M., Vyzula, R., Slaby, O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012;10:55. doi: 10.1186/1479-5876-10-55. (IF2011: 3,474)
Slaby, O., Redova, M., Poprach, A., Nekvindova, J., Iliev, R., Radova, L., Lakomy, R., Svoboda, M., Vyzula, R. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012;51(7):707-716. doi: 10.1002/gcc.21957. (IF2011: 3,306)
Vítek, L. Serum bilirubin levels and the risk of Crohn's disease. J Crohns Colitis 2012;6(6):732; author reply 733. doi: 10.1016/j.crohns.2012.03.010. (IF2011: 2,566)
Zapletalova, D., André, N., Deak, L., Kyr, M., Bajciova, V., Mudry, P., Dubska, L., Demlova, R., Pavelka, Z., Zitterbart, K., Skotakova, J., Husek, K., Martincekova, A., Mazanek, P., Kepak, T., Doubek, M., Kutnikova, L., Valik, D., Sterba, J. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. Oncology 2012;82(5):249-260. doi: 10.1159/000336483. (IF2011: 2,267)